Company Description
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility.
Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings.
HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista® wavECG™ device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers.
HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging.
The MyoVista® also provides conventional ECG information in the same test.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 15, 2022 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Andrew Simpson |
Contact Details
Address: 550 Reserve St, Suite 360 Southlake, Texas 76092 United States | |
| Phone | 682-237-7781 |
| Website | heartsciences.com |
Stock Details
| Ticker Symbol | HSCS |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| IPO Price | $4.25 |
| CIK Code | 0001468492 |
| CUSIP Number | 42254E104 |
| ISIN Number | US42254E1047 |
| Employer ID | 26-1344466 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Andrew Simpson | Chief Executive Officer, President and Chairman of the Board of Directors |
| Danielle Watson | Chief Financial Officer and Treasurer |
| Mark T. Hilz | Chief Operating Officer, Secretary and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 4, 2024 | 8-K | Current Report |
| May 22, 2024 | 8-K | Current Report |
| May 16, 2024 | 8-K/A | [Amend] Current report |
| May 15, 2024 | 8-K | Current Report |
| May 10, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 424B3 | Prospectus |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 14, 2024 | 10-Q | Quarterly Report |
| Mar 13, 2024 | EFFECT | Notice of Effectiveness |
| Mar 11, 2024 | UPLOAD | Filing |